Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up

Glaxosmithkline Share Price (GSK)

Show Chart Filters
Time period:
Moving Average:
Compare to:
Price 1,318.60on 18-02-2018at 16:30:00
Change 0.00 1.40%
Buy 1,319.40
Sell 1,319.20
Buy / Sell GSK Shares
Last Trade: Sell 4,777 at 1,318.60p
Day's Volume: 10,049,842
Last Close: 1,318.60p
Open: 1,309.00p
ISIN: GB0009252882
Day's Range 1,302.80p - 1,322.20p
52wk Range: 1,236.40p - 1,724.50p
Market Capitalisation: £65,379m
VWAP: 0.00p
Shares in Issue: 4,958m

Recent Trades History Glaxosmithkline (GSK)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell*4,7771,318.6018:06:30 - 16-Feb-18
Sell*8,5981,317.18118:38:25 - 16-Feb-18
Sell*4761,310.6318:38:17 - 16-Feb-18
Sell*11,1461,317.73718:12:51 - 16-Feb-18
Sell*11,1461,317.73718:12:51 - 16-Feb-18
Buy*15,9231,319.87218:11:00 - 16-Feb-18
Buy*131,333.06018:09:31 - 16-Feb-18
Buy*7721,343.40218:06:49 - 16-Feb-18
Buy*9461,320.5118:00:32 - 16-Feb-18
Sell*15,7601,312.84718:00:00 - 16-Feb-18

Share Price History for Glaxosmithkline

Time period:
to
Frequency:
Date Open High Low Close Volume
16th Feb 2018 (Fri)1,309.001,322.201,302.801,318.6010,231,728
15th Feb 2018 (Thu)1,293.601,309.001,287.001,300.408,446,760
14th Feb 2018 (Wed)1,293.401,296.401,277.801,290.8014,183,359
13th Feb 2018 (Tue)1,291.801,296.201,284.401,291.007,970,287
12th Feb 2018 (Mon)1,306.401,308.401,291.601,292.6015,393,254
9th Feb 2018 (Fri)1,290.601,300.401,282.201,291.0013,904,699
8th Feb 2018 (Thu)1,286.801,331.801,285.001,303.8020,549,235
7th Feb 2018 (Wed)1,260.001,294.801,243.001,285.4018,605,303
6th Feb 2018 (Tue)1,250.001,263.001,236.401,242.8015,524,770
5th Feb 2018 (Mon)1,296.001,296.801,276.201,280.4015,219,462
2nd Feb 2018 (Fri)1,297.001,315.801,295.601,310.809,226,799
1st Feb 2018 (Thu)1,313.401,318.801,306.001,309.6010,433,907
31st Jan 2018 (Wed)1,332.601,340.801,318.401,320.4010,595,122
30th Jan 2018 (Tue)1,342.001,355.601,336.801,341.009,459,672
29th Jan 2018 (Mon)1,355.001,357.601,344.201,349.007,586,166
26th Jan 2018 (Fri)1,338.601,358.601,335.001,355.0010,531,979
25th Jan 2018 (Thu)1,342.801,349.601,330.301,335.009,240,614
24th Jan 2018 (Wed)1,358.201,364.801,340.401,347.0012,438,259
23rd Jan 2018 (Tue)1,351.401,375.801,350.301,364.408,658,596
22nd Jan 2018 (Mon)1,356.201,364.401,352.001,355.206,636,713
19th Jan 2018 (Fri)1,351.401,388.301,299.601,358.0010,112,453

GSK - Glaxosmithkline Investor Summary

GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.

If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.

On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.

News about Glaxosmithkline (GSK)

FTSE Strong as Markets Wait for Service Sector News

News - Wednesday, July 05, 2017

The FTSE 100 got off to a strong start, as investors waited for the publication of the Markit Survey data, which implied that little had changed month on month for June....

Why The FTSE Didn’t Crash After Trump

News - Thursday, November 10, 2016

In the immediate aftermath of the US Presidential Election, the FTSE 100 did slip slightly, but it was not the massive crash that some had predicted. Indeed, a number of companies in the UK’s leading index made significant gains....

FTSE 100 Latest
Value7,294.70
Change59.89

Login to your account

Forgot Password?

Not Registered